康辰药业
(603590)
| 流通市值：47.64亿 | | | 总市值：48.29亿 |
| 流通股本：1.57亿 | | | 总股本：1.59亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 212,002,399.05 | 825,397,797.2 | 646,310,729.73 | 405,024,853.01 |
| 营业收入 | 212,002,399.05 | 825,397,797.2 | 646,310,729.73 | 405,024,853.01 |
| 二、营业总成本 | 152,416,687.23 | 696,236,061.61 | 518,431,065.74 | 317,146,155.19 |
| 营业成本 | 20,909,945.62 | 86,125,361.11 | 68,708,878.94 | 42,387,416.16 |
| 税金及附加 | 1,222,007.45 | 6,745,994.41 | 5,190,277.67 | 3,455,661 |
| 销售费用 | 90,013,005.63 | 418,444,627.71 | 322,345,827.07 | 193,746,682.98 |
| 管理费用 | 32,879,012.54 | 135,311,648.72 | 89,275,691.13 | 56,522,302.28 |
| 研发费用 | 8,078,499.71 | 54,937,808.73 | 35,041,400.54 | 23,294,981.62 |
| 财务费用 | -685,783.72 | -5,329,379.07 | -2,131,009.61 | -2,260,888.85 |
| 其中:利息费用 | 1,936,052.73 | 6,155,499.15 | 4,375,208.79 | 2,637,685.12 |
| 其中:利息收入 | 3,393,168.72 | 12,833,810.36 | 9,559,067.6 | 6,359,917.75 |
| 加:公允价值变动收益 | -122,989.78 | -486,686.56 | 1,599,401.32 | 923,478.38 |
| 加:投资收益 | 540,637.31 | 18,142,328.06 | 12,201,416.52 | 10,109,565.73 |
| 资产处置收益 | 88,495.58 | -7,331.58 | -7,331.58 | - |
| 资产减值损失(新) | - | -105,547,311.98 | - | - |
| 信用减值损失(新) | -4,578,317.13 | -6,423,851.6 | -585,167.98 | -180,061.9 |
| 其他收益 | 1,338,860.01 | 4,248,923.24 | 3,313,438.42 | 2,201,276.16 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 56,852,397.81 | 39,087,805.17 | 144,401,420.69 | 100,932,956.19 |
| 加:营业外收入 | 10,231.9 | 2,630.45 | 1,335.25 | 978.72 |
| 减:营业外支出 | 1,312,269.8 | 226,688.07 | 190,501.27 | 129,648.52 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 55,550,359.91 | 38,863,747.55 | 144,212,254.67 | 100,804,286.39 |
| 减:所得税费用 | 7,412,809.54 | 17,333,203 | 20,688,703.01 | 13,523,270.03 |
| 六、净利润 | 48,137,550.37 | 21,530,544.55 | 123,523,551.66 | 87,281,016.36 |
| 持续经营净利润 | 48,137,550.37 | 21,530,544.55 | 123,523,551.66 | 87,281,016.36 |
| 归属于母公司股东的净利润 | 44,497,393.8 | 42,216,726.62 | 112,975,682.11 | 79,202,846.22 |
| 少数股东损益 | 3,640,156.57 | -20,686,182.07 | 10,547,869.55 | 8,078,170.14 |
| (一)基本每股收益 | 0.28 | 0.27 | 0.72 | 0.5 |
| (二)稀释每股收益 | 0.28 | 0.27 | 0.72 | 0.5 |
| 八、其他综合收益 | -38,283,346.86 | 58,297,183.27 | 51,595,510.65 | 18,880,650.61 |
| 归属于母公司股东的其他综合收益 | -38,283,346.86 | 58,297,183.27 | 51,595,510.65 | 18,880,650.61 |
| 九、综合收益总额 | 9,854,203.51 | 79,827,727.82 | 175,119,062.31 | 106,161,666.97 |
| 归属于母公司股东的综合收益总额 | 6,214,046.94 | 100,513,909.89 | 164,571,192.76 | 98,083,496.83 |
| 归属于少数股东的综合收益总额 | 3,640,156.57 | -20,686,182.07 | 10,547,869.55 | 8,078,170.14 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-30 | 2024-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |